The Federal Government says it did not receive any batch of the AstraZeneca vaccine with a suspected side effect.
In a statement by the National Primary Health Care Development Agency (NPHCDA) on Thursday, the FG admitted that while an investigation is still ongoing, the side effect observed so far is mild and not related to those in Europe.
No fewer than six European nations have suspended the Astrazeneca vaccine after several serious cases of blood clots among vaccinated people.
But the NPHCDA in the statement signed by its Head, Public Relations Unit, Mohammad Ohitoto, said it will continue to monitor the developments regarding the ABV5300 batch and will share further information as it becomes available.
It, however, urged Nigerians to be confident in the nation’s vaccine programme.
Read the full statement below:
We are aware of precautionary concerns that have been raised regarding one specific batch of the AstraZeneca vaccine, namely ABV5300.
We understand that investigations are being conducted to determine if the batch is in any way linked to an observed side effect.
While we await the outcome of the investigations, it is important to clearly state that Nigeria did not receive any doses from the batch of vaccines that is at issue.
Vaccinations in Nigeria started earlier this month and we have not observed any similar adverse reactions. All side effects reported by those who have been administered the vaccine have been mild.
We are satisfied that the clinical evidence indicates the Oxford-AstraZeneca vaccine to be safe and effective.
Our assessment is in line with countries such as Spain and the UK who have indicated that they will continue to administer the vaccine because it remains an important tool to protect against COVID-19.
The safety of vaccines delivered to Nigeria is paramount to the Presidential Task Force on COVID-19.
For this reason, it has enhanced multi-sectoral collaboration among stakeholders and technical entities such as the FMOH, NPHCDA, NAFDAC, WHO and UNICEF whose cooperation ensures the highest global standards are met for vaccines delivered to Nigeria before they are distributed to Nigerians.
Clear, rigorous protocols are being followed to safeguard the health of Nigerians.
We are continuing to monitor the developments regarding the ABV5300 batch and will share further information as it becomes available.
In the meantime, we encourage Nigerians who are among those being prioritized in the current phase to continue their confidence and enthusiasm for our vitally important national vaccine program. Together, we can save lives.
